C-MNY7Deep Origin
physics-based AI, molecular modeling, drug discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MNY7
C-MNY7C-MNY7physics-based AI, molecular modeling, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Deep Origin physics-based AI, molecular modeling, drug discovery
Deep Origin develops an AI-powered drug discovery platform combining molecular physics with AI acceleration. Its tools include Balto, DO Studio, DO Patent, docking, virtual screening, and free-energy perturbation workflows. The company works through SaaS platform access, research partnerships, and out-licensing or co-development of validated assets including CD73 and GPR75 programs.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Deep Origin — Early mechanism · Lower middle. Derived deterministically from 9 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic